Stocks
Alnylam Pharmaceuticals (ALNY) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -395.0% | -149.4% | -78.4% | -89.3% | -14.1% | -6.25% | ||
| Changes by years, y/y, % | +720pp | +246pp | +71pp | -11pp | +75pp | -58.3% | |||
Alnylam Pharmaceuticals. EBITDA margin, %
Alnylam Pharmaceuticals. EBITDA margin, changes, pp
Alnylam Pharmaceuticals (ALNY) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | 26.0% | -21.1% | -3.00% | 5.62% | -12.0% | -6.25% | |
| Changes by years, y/y, % | +115pp | +32pp | +42pp | +82pp | -38pp | |||
| Changes by quarters, q/q, % | +103pp | -47pp | +18pp | +9pp | -18pp | |||
